Baricitinib is effective and safe in the real-world management of severe AA, especially when initiated early in patients with lower baseline severity and elevated ESR. These findings highlight the relevance of timely intervention and appropriate patient selection.
No takes yet. Share an insight, caveat, or question.
García‐Moronta et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: